Kiora Pharmaceuticals Inc.
KPRX evidence brief
What we can confirm
- BioSniper Score:
- 8.4 / 10
- Market Cap:
- $11.7M
- Lead Asset:
- kio-101 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for KPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KPRX
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biotech developing photoswitch small-molecule therapies for retinal diseases, with a lead candidate KIO-301 in Phase 2 for retinitis pigmentosa and a partnered KIO-104 program in Phase 2 for retinal inflammation.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$11.7M
Cash Runway
—
Lead Asset
kio-101 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials for Kiora Pharmaceuticals Inc..
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biotech developing photoswitch small-molecule therapies for retinal diseases, with a lead candidate KIO-301 in Phase 2 for retinitis pigmentosa and a partnered KIO-104 program in Phase 2 for retinal inflammation.
- Lead candidate KIO-301 is a small-molecule photoswitch designed to restore light perception in degenerative retinal diseases; it received FDA Orphan Drug Designation in March 2022 [sec_mda · as of 2026-08-07].
- In January 2024, Kiora entered a License Agreement with Théa Open Innovation (TOI) for KIO-301, receiving a $16M upfront payment and up to $285M in milestones plus tiered royalties [sec_mda · as of 2026-05-08].
- KIO-104 Phase 2 trial (KLARITY-1) for macular edema began enrollment in Q2 2025 and dosing in Q3 2025 [sec_mda · as of 2026-08-07].
- As of June 30, 2026, Kiora reported cash & equivalents of $7.1M, net income of -$2.1M, and shareholders' equity of $16.9M [sec].
- Kiora has incurred annual losses and negative cash flows since inception, with the exception of 2024 due to the TOI upfront payment, and future losses are anticipated [sec_mda · as of 2026-08-07].
What works
- KIO-301 has Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the EU, providing potential market exclusivity and development incentives [sec_mda · as of 2026-08-07].
- The TOI partnership provides non-dilutive funding ($16M upfront) and covers R&D costs, with TOI holding global rights (ex-Asia) to co-develop and commercialize KIO-301 [pipeline].
- KIO-104 showed in earlier studies that it reduced macular edema and was well tolerated with no serious adverse events [sec_mda · as of 2026-03-25].
What to weigh
- Kiora has a history of annual losses and negative cash flows since inception, with future losses anticipated; the only profitable year was 2024 due to the TOI upfront payment [sec_mda · as of 2026-08-07].
- Cash and equivalents of $7.1M as of June 30, 2026 may only fund operations into late 2027, and additional capital will be needed to complete product development [sec_mda · as of 2026-03-25].
- The company halted development of anterior segment assets KIO-101 and KIO-201, and KIO-201 was impaired, indicating pipeline narrowing and reliance on partnership for KIO-101 [sec_mda · as of 2026-03-25].
From the filings
Quoted directly from source documents.
Kiora entered a License Agreement with TOI for KIO-301 with $16M upfront and up to $285M milestones.
“Kiora received an upfront, payment of $16 million; up to $285 million upon achievement of pre-specified clinical”
SEC MD&A · May 8, 2026
KIO-104 Phase 2 trial began enrollment in Q2 2025 and dosing in Q3 2025.
“we received approval to start enrolling patients in a Phase 2 trial for KIO-104 in retinal inflammation and began enrollment in the second quarter of 2025. Dosing began in the third quarter of 2025.”
SEC MD&A · August 7, 2026
Kiora has incurred annual losses and negative cash flows since inception, except for 2024.
“With the exception of the year ended December 31, 2024, Kiora has incurred annual losses and negative cash flows since inception, and future losses are anticipated.”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2022-11-10 · Phase2_Start: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) — This trial is ongoing; data updates may inform KIO-301's efficacy and safety profile.
- 2025-05-01 · Phase2_Start: A Phase 2, Open-label, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1) — Enrollment and dosing have begun; results will determine KIO-104's potential for retinal inflammation.
- 2025-08-29 · Phase2_Start: A Phase II, Randomised, Controlled, Double Masked, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa — This randomized controlled trial will provide key comparative data for KIO-301 in late-stage disease.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $7.1M as of June 30, 2026 may only fund operations into late 2027; additional capital needed [sec_mda · as of 2026-03-25].
- History of losses — Annual losses and negative cash flows since inception except for 2024; future losses anticipated [sec_mda · as of 2026-08-07].
- Pipeline concentration — Only two active programs (KIO-301 and KIO-104); anterior segment assets halted or impaired [sec_mda · as of 2026-03-25].
- Dependence on partnership — KIO-301 development and commercialization depend on TOI; KIO-101 requires a partner [sec_mda · as of 2026-08-07].
What to watch
- Progress of KIO-301 Phase 2 trial (ABACUS) for retinitis pigmentosa and choroideremia, with data readouts [catalyst].
- Enrollment and dosing updates for KIO-104 Phase 2 trial (KLARITY-1) for macular edema [sec_mda · as of 2026-08-07].
- Ability to secure additional capital or partnership to extend cash runway beyond late 2027 [sec_mda · as of 2026-03-25].
- Potential partnership or licensing deal for KIO-101 topical eye drop program [sec_mda · as of 2026-08-07].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Kiora Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kiora Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.41 · 0% dilution
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.7%
- Days to cover
- 0.0
- Shares short
- 30,793
- Daily short volume (Oct 12, 2026)
- 25.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KPRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kiora Pharmaceuticals Inc.?
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biotech developing photoswitch small-molecule therapies for retinal diseases, with a lead candidate KIO-301 in Phase 2 for retinitis pigmentosa and a partnered KIO-104 program in Phase 2 for retinal inflammation.
What is Kiora Pharmaceuticals Inc.'s lead drug candidate?
Kiora Pharmaceuticals Inc.'s most advanced tracked candidate is kio-101 (Phase 2) for Ocular manifestation of autoimmune diseases (OPRA+).
Who is the CEO of Kiora Pharmaceuticals Inc.?
Dr. Brian M. Strem Ph.D. is the chief executive officer of Kiora Pharmaceuticals Inc. (KPRX).
Where is Kiora Pharmaceuticals Inc. headquartered?
Kiora Pharmaceuticals Inc. (KPRX) is headquartered in Encinitas, CA, United States.
What therapeutic areas does Kiora Pharmaceuticals Inc. focus on?
Kiora Pharmaceuticals Inc. develops therapies across Oncology, Immunology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.